Cas:158008-69-6 4-cyano-3-hydroxybutanamide manufacturer & supplier

We serve Chemical Name:4-cyano-3-hydroxybutanamide CAS:158008-69-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-cyano-3-hydroxybutanamide

Chemical Name:4-cyano-3-hydroxybutanamide
CAS.NO:158008-69-6
Synonyms:Butanamide,4-cyano-3-hydroxy
Molecular Formula:C5H8N2O2
Molecular Weight:128.12900
HS Code:2926909090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:87.11000
Exact Mass:128.05900
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Butanamide,4-cyano-3-hydroxy chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Butanamide,4-cyano-3-hydroxy physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Butanamide,4-cyano-3-hydroxy Use and application,Butanamide,4-cyano-3-hydroxy technical grade,usp/ep/jp grade.


Related News: The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1 4-[4-(Benzyloxycarbonylamino-methyl)-cyclohexanecarbonyloxy]-3-nitro-benzoic acid methyl ester manufacturers Conducted by Innovent in China, the CIBI321A101 trial is a Phase 1a open-label, multi-center study of the safety, tolerability and primary efficacy of IBI321 in patients with advanced solid tumors. Phase 1a of the study will evaluate dosing of IBI321 in a variety of solid tumors (ClinicalTrials.gov, NCT04911894). 1-((13,24,33,43,53,63-hexaoxin-2-yl)oxy)-1H-13,23,33,44,54,63,74,83,93,103,113,124,134-hexaoxino[6,1-f]pentaoxolo[4,5-d]hexaoxin-5-ol suppliers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. 1-(3-Bromo-phenyl)-6-methoxy-2-phenyl-3,4-dihydro-isoquinolinium; iodide vendor & factory.